Table 3.

Adherence to mepolizumab

Descriptive statistics
Proportion of days covered (PDC, (mean))	0.7
PDC (median)	0.8
No/per cent patients by PDC category	% (n)
PDC≥25%	91 (1643)
PDC≥50%	77 (1377)
PDC≥75%	62 (1107)
PDC=100%	2 (38)
No/per cent patients	% n
Early-stage persistence	65 (1176)
Discontinuation by catgeory	% (n)
No refill within 3 months	11 (202)
No refill within 6 months	7 (120)
No refill within 9 months	6 (106)
No refill within 12 months	6 (99)
Time to discontinuation	No of days
Mean	68
Median	28
With 28-day allowable gap (mean)	233
With 28-day allowable gap (median)	271

N=1801.